Evaluation of AXR-270 for the Treatment of Posterior Blepharitis Associated With Meibomian Gland Dysfunction

Completed · Phase 2

Conditions studied: Posterior Blepharitis, Meibomian Gland Dysfunction

In brief

This study will evaluate the safety, tolerability and efficacy of AXR-270 Cream in treating posterior blepharitis associated with Meibomian Gland Disease (MGD)

Key facts

Study ID

NCT04469998

Run by

AxeroVision, Inc.

People needed

129

Starts

2020-06-16

Expected to finish

2020-12-31

Last updated by the study team

2023-07-21

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female, 18 years or older
• Have a clinical diagnosis of moderate to severe MGD (total MGD score between 5 and 14 on a scale with a range between 0 and 15; and clinical severity score of eyelid margin vascularity of at least 2 (moderate))
• Have a score of ≥35 on Eye Discomfort using VAS
• Have a tFCS score between 3 and 14 on the NEI scale
• Have a Schirmer score of >7 mm
• Have a OSDI score >30
• If female, then subject should be non-pregnant and non-lactating

You may not qualify if…

• Subjects with iritis, uveitis in either eye
• Subjects with conjunctivitis, keratitis, severe anterior keratitis not related to MGD
• Subjects with lid abnormalities
• Subjects with ocular fungal, viral or bacterial infection
• Subjects unable or unwilling to withhold the use of eyelid scrubs
• Subjects with glaucoma and serious systemic disease

Where it is running

• AxeroVision, Inc. — Carlsbad, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.